Published in Patient Prefer Adherence on January 17, 2015
Serum Metabolite Biomarkers Discriminate Healthy Smokers from COPD Smokers. PLoS One (2015) 0.78
Bronchodilator efficacy of 18 μg once-daily tiotropium inhalation via Discair(®) versus HandiHaler(®) in adults with chronic obstructive pulmonary disease: randomized, active-controlled, parallel-group, open-label, Phase IV trial. Int J Chron Obstruct Pulmon Dis (2016) 0.75
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2007) 47.86
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2012) 22.96
A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med (2008) 17.19
A measure of quality of life for clinical trials in chronic lung disease. Thorax (1987) 10.87
The clinical diagnosis of pulmonary emphysema; an experimental study. Proc R Soc Med (1952) 9.41
The St George's Respiratory Questionnaire. Respir Med (1991) 8.49
Development and first validation of the COPD Assessment Test. Eur Respir J (2009) 8.06
Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med (2013) 6.36
The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest (1984) 5.19
Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res (2010) 5.17
Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med (1999) 4.65
Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J (2008) 4.53
Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes (2003) 4.41
An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med (2012) 3.62
Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis (1994) 3.59
Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax (2009) 3.54
Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax (2003) 2.93
Perceived exertion: a note on "history" and methods. Med Sci Sports (1973) 2.81
Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review. Ann Intern Med (2012) 2.81
Mortality trends in chronic obstructive pulmonary disease in Europe, 1994-2010: a joinpoint regression analysis. Lancet Respir Med (2013) 2.56
The clinical and genetic features of COPD-asthma overlap syndrome. Eur Respir J (2014) 2.27
Spanish guideline for COPD (GesEPOC). Update 2014. Arch Bronconeumol (2014) 2.15
Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin (2009) 1.98
Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J (2003) 1.84
Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J (2010) 1.78
Consensus document on the overlap phenotype COPD-asthma in COPD. Arch Bronconeumol (2012) 1.68
The measurement of fatigue in chronic illness: a systematic review of unidimensional and multidimensional fatigue measures. J Pain Symptom Manage (2009) 1.53
Aclidinium bromide for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2014) 1.51
Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J (2012) 1.50
The PROactive innovative conceptual framework on physical activity. Eur Respir J (2014) 1.47
Beyond FEV₁ in COPD: a review of patient-reported outcomes and their measurement. Int J Chron Obstruct Pulmon Dis (2012) 1.47
Lung deposition of aclidinium bromide from Genuair, a multidose dry powder inhaler. Respiration (2009) 1.45
Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD. Chest (2011) 1.40
Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD (2012) 1.37
Predictors of adherence to inhaled medications among Veterans with COPD. J Gen Intern Med (2012) 1.33
Potential risk factors for medication non-adherence in patients with chronic obstructive pulmonary disease (COPD). Eur J Clin Pharmacol (2012) 1.25
Development and validation of the Capacity of Daily Living during the Morning questionnaire and the Global Chest Symptoms Questionnaire in COPD. Eur Respir J (2009) 1.24
Living with chronic obstructive pulmonary disease: a survey of patients' knowledge and attitudes. Respir Med (2009) 1.24
Validation of a vertical visual analogue scale as a measure of clinical dyspnea. Rehabil Nurs (1989) 1.21
Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers. J Med Econ (2011) 1.19
Impact of patients' satisfaction with their inhalers on treatment compliance and health status in COPD. Respir Med (2013) 1.15
Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. Eur J Health Econ (2007) 1.13
Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD. COPD (2010) 1.06
Evaluation of Quality of Life instruments for use in COPD care and research: a systematic review. Int J Nurs Stud (2012) 1.04
Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. J Pharmacol Exp Ther (2009) 1.02
Adherence to long-acting inhaled therapies among patients with chronic obstructive pulmonary disease (COPD). COPD (2012) 1.01
The impact of COPD on health status: findings from the BOLD study. Eur Respir J (2013) 1.01
The influence of informal caregivers on adherence in COPD patients. Ann Behav Med (2012) 1.01
Long-term safety and efficacy of twice-daily aclidinium bromide in patients with COPD. Respir Med (2013) 1.00
ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clin Drug Investig (2013) 0.97
Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. Eur J Pharm Sci (2010) 0.97
Factors associated with medication adherence in patients with chronic obstructive pulmonary disease. Respiration (2011) 0.96
Development and validation of a cough and sputum assessment questionnaire. Respir Med (2008) 0.95
Peak inspiratory flow through the Genuair inhaler in patients with moderate or severe COPD. Respir Med (2009) 0.95
Variability of hospital resources for acute care of COPD patients: the European COPD Audit. Eur Respir J (2013) 0.92
Preference, satisfaction and errors with two dry powder inhalers in patients with COPD. Expert Opin Drug Deliv (2013) 0.92
Improving inhaler adherence in patients with chronic obstructive pulmonary disease: a cost-effectiveness analysis. Respir Res (2014) 0.92
Development, dimensions, reliability and validity of the novel Manchester COPD fatigue scale. Thorax (2009) 0.91
Characterisation and impact of reported and unreported exacerbations: results from ATTAIN. Eur Respir J (2014) 0.91
The development of a patient-reported outcome measure for assessing nighttime symptoms of chronic obstructive pulmonary disease. Health Qual Life Outcomes (2013) 0.89
One-year extension study of ACCORD COPD I: safety and efficacy of two doses of twice-daily aclidinium bromide in patients with COPD. COPD (2013) 0.88
Characteristics of patients with COPD newly prescribed a long-acting bronchodilator: a retrospective cohort study. Int J Chron Obstruct Pulmon Dis (2014) 0.88
Moving towards patient-centered medicine for COPD management: multidimensional approaches versus phenotype-based medicine--a critical view. COPD (2014) 0.87
Development and psychometric assessment of the COPD and Asthma Sleep Impact Scale (CASIS). Health Qual Life Outcomes (2009) 0.82
Tiotropium HandiHaler improves the survival of patients with COPD: a systematic review and meta-analysis. J Aerosol Med Pulm Drug Deliv (2013) 0.82
Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases. Ther Adv Chronic Dis (2014) 0.82
Differences in classification of COPD patients into risk groups A-D: a cross-sectional study. BMC Res Notes (2014) 0.81
Tiotropium improves walking endurance in COPD. Eur Respir J (2011) 0.80
Impact of adherence to treatment with tiotropium and fluticasone propionate/salmeterol in chronic obstructive pulmonary diseases patients. Curr Med Res Opin (2014) 0.80
Pharmacokinetics and safety of aclidinium bromide in younger and elderly patients with chronic obstructive pulmonary disease. Int J Clin Pharmacol Ther (2012) 0.80
Factors associated with early adherence to tiotropium in chronic obstructive pulmonary disease. Chron Respir Dis (2012) 0.80
Defining patient-reported outcomes in chronic obstructive pulmonary disease: the patient-centered experience. Med Clin North Am (2012) 0.78
Development and validity of the Patient-centred COPD Questionnaire (PCQ). J Psychosom Res (2013) 0.76
Clustering of unhealthy lifestyle behaviors is associated with a low adherence to recommended preventive practices among COPD patients in Spain. COPD (2014) 0.75